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Malignant	Hyperthermia
David	 J.	Kanotz,	BSN,	CCRN	
Introduction
Otterbein	University,	Westerville,	Ohio
Each	year,	 thousands	of	inpatient	and	outpatient	surgeries	are	performed	 daily	in	the	United	States.		During	surgery,	 advanced	practice	nurses	and	physicians	must	attentively	monitor	 their	patients	for	possible	unforeseen	complications	that	can	arise	intra	or	post	operatively	such	as	malignant	hyperthermia	(MH).	 	Malignant	hyperthermia	 is	a	life-threatening	skeletal	muscle	disorder	that	presents	as	a	hypermetabolic	response	 to	several	inhaled	anesthetics	and	to	 the	depolarizing	muscle	relaxant	succinylcholine.		It	is	extremely	important	 for	certified	registered	nurse	anesthetists	(CRNA)	to	understanding	 the	pathophysiology,	 clinical	symptoms,	and	 treatment	plan	of	MH	due	 to	their	vital	role	 in	managing	these	patients	 in	the	operating	 room.
Signs	and	Symptoms
Having	knowledge	of	the	signs	and	symptoms	that	occur	early	and	manifest	late	during	an	episode	of	malignant	hyperthermia	 can	have	a	profound	 effect	on	the	outcome	of	patients.	 	Rosenberg,	Pollock,	Schiemann,	Bulger,	&	Stowell (2015)	explain	that,	 “…	early	recognition	of	the	signs	of	MH	and	routine	use	of	core	 temperature	monitoring	are	essential	in	minimizing	morbidity	and	mortality	from	MH”	 (p.3).	 	Like	any	other	medical	condition,	clinical	symptoms	can	differ	patient	to	patient.	Malignant	hyperthermia	can	develop	as	a	gradual	onset	of	 clinical	symptoms,	to	an	abrupt,	 life	threatening	situation.		 Some	of	 these	clinical	features	include,	but	are	not	 limited	to:	rising	patient	 temperature,	 tachycardia,	muscle	rigidity,	decreased	Sao2,	 cola-colored	urine,	 and	a	rise	in	end-tidal	CO2	>55	mmHg.	 “A	rise	in	the	patient’s	end-tidal	carbon	dioxide	(Etco2)	 concentration	 is	often	the	earliest	indication	of	malignant	hyperthermia”	(Carpenter,	 LaRiccia,	&	Papadakos,	2015,	 p.	45).	 	By	monitoring	end-tidal	 carbon	dioxide	during	 surgery,	Certified	Registered	Nurse	Anesthetist	(CRNA)	and	anesthesiologist	are	able	to	detect	early	increases	in	exhaled	carbon	dioxide,	 therefore	prompting	 them	to	start	assessing	the	underlying	causes.	Although	MH	 is	notable	 for	high	body	 temperatures,	 this	sign	may	often	come	later	than	some	of	the	other	symptoms.	“Hyperthermia,	 which		may	climb	at	a	rate	of	1° to	2 °C	every	5	minutes	and	exceed	43.3 ° C	 (110 ° F),	 is	often	a	late	but	confirming	sign	of	MH”	 (Nagelhaus &	Plaus,	2013,	 p.	792).	 The	combination	of	symptoms	including	acidosis,	hyperkalemia,	and	hyperthermia	can	potentially	lead	to	cardiac	irritability	and	arrhythmias.	Therefore,	 cardiac	monitoring	 is	essential	for	patients	undergoing	 surgery	and	receiving	inhaled	anesthetics.		Knowing	the	signs	and	symptoms	of	MH	and	identifying	them	early	can	have	drastic	effects	on	the	mortality	of	patients.	
Pathophysiology
Understanding	 the	pathophysiological	effects	of	MH	are	important	 in	understanding	 the	clinical	symptoms	and	treatment	plan.	Malignant	Hyperthermia	 is	a	rare,	 autosomal-dominant	disorder	 in	which	mutations	of	the	ryanodine	 receptor	 type	1,	 located	in	 the	sarcoplasmic	reticulum,	cause	uncontrolled	release	of	calcium	leading	to	prolonged	 muscle	fiber	contraction	(Carpenter,	 LaRiccia,	&	Papadakos,	2015,	 p.	46).	 	This	occurs	when	patients	who	have	this	particular	mutation	receive	inhaled	anesthetics,	or	 the	depolarizing	muscle	relaxant	succinylcholine.	Due	to	the	 large	amount	of	 calcium	released	from	the	sarcoplasmic	reticulum,	skeletal	muscle	throughout	 the	body	contracts	and	causes	a	massive	increase	in	muscle	metabolism.	According	to	Nagelhout &	Plaus (2014),	“skeletal	muscle	constitutes	40%	to	50%	 of	our	body	mass,	so	relatively	small	changes	in	muscle	metabolism	may	produce	 the	dramatic	systemic	biochemical	changes	observed	with	MH”	(p.	792).	 	As	the	MH	develops,	 the	sarcoplasmic	reticulum	becomes	damaged,	 therefore	releasing	potassium,	creatine kinase,	and	myoglobin	 to	the	extracellular	fluid.	Which	is	why	symptoms	of	MH	include:	elevated	potassium	and	creatine kinase	levels,	as	well	as	dark	cola-colored	urine	 (myoglobin).	
Significance	of
Pathophysiology
As	stated	earlier,	 it	is	important	 for	healthcare	providers	 to	know	and	understand	the	pathophysiology	of	MH.	By	doing	so,	diagnoses	and	 treatment	can	be	 implemented	early,	hopefully	decreasing	the	chance	of	significant	damage	to	the	patient.	One	of	the	most	important	 treatments	 to	initiate	early	is	to	remove	 the	triggering	anesthetic	as	soon	as	possible.	Seifert,	Wahr,	Pace,	Cochrane,	 &	Bagnola (2014)	 explain	that,	 “untreated	 MH	can	produce	 cardiac	arrest,	kidney	and	 liver	failure,	abnormal	blood	coagulation,	internal	hemorrhage,	 neurological	injury,	 cardiovascular	collapse,	and	death”	 (p.	 189).	 In	any	medical	condition,	knowledge	of	 the	underlying	 cause	can	help	healthcare	providers	 interpret	 signs	and	symptoms,	and	distinguish	different	diagnoses.	
Implications	 for	
Nursing	Care
Nurse	Anesthetists	and	Anesthesiologists	are	at	the	 forefront	of	patient	care	in	 the	operating	room,	 therefore	 it	is	extremely	important	 for	them	to	implement	care	as	soon	as	possible	when	someone	is	suspected	of	developing	MH.		One	of	the	first	steps	in	preventing	 issues	is	interviewing	patients	before	surgery	and	retrieving	a	medical	and	family	history.	This	is	especially	important	since	MH	is	an	autosomal-dominant	disorder.	 “Family	members	(ie,	children,	 siblings)	of	a	patient	with	MH	susceptibility	have	a	50%	chance	of	inheriting	a	gene	defect	for	MH	and	becoming	MH	susceptible”	(Seifert,	Wahr,	Pace,	Cochrane,	&	
Bagnola,	2014,	 	p.	190).	 	When	MH	 is	suspected,	it	is	vital	that	the	operating	room	staff	works	cohesively	to	collect	materials	and	medications	to	 treat	the	patient.	Emergency	 interventions	that	are	required	 include	obtaining	a	cooling	blanket	and	 ice	to	treat	hyperthermia,	correcting	acidosis,	increasing	the	patients	fraction	of	 inspired	oxygen	to	100%	 and	ventilation,	discontinuing	anesthetics	if	possible,	grabbing	 the	MH	cart,	 and	giving	Dantrolene.	Dantrolene must	be	given	as	soon	as	possible	to	prevent	serious	damage	 to	the	patient.	 “Dantolene …is	a	skeletal	muscle	relaxant	that	 inhibits	the	excitation-contraction	in	skeletal	muscle	without	affecting	muscle	electrical	properties”	(Carpenter,	 LaRiccia,	and	Papadakos,	2015,	 p.	47).	 Quick	and	 immediate	action	by	 the	operating	room	staff,	CRNA,	and	anesthesiologist	can	have	profound	 effects	on	the	outcome	of	patients	with	MH.	
Conclusion
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